RT Journal Article
SR Electronic
T1 Population-based sero-epidemiological estimates of real-world vaccine effectiveness against Omicron infection in an infection-naive population, Hong Kong, January to July 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.01.22281746
DO 10.1101/2022.11.01.22281746
A1 Jonathan J Lau
A1 Samuel MS Cheng
A1 Kathy Leung
A1 Cheuk Kwong Lee
A1 Asmaa Hachim
A1 Leo CH Tsang
A1 Kenny WH Yam
A1 Sara Chaothai
A1 Kelvin KH Kwan
A1 Zacary YH Chai
A1 Tiffany HK Lo
A1 Masashi Mori
A1 Chao Wu
A1 Sophie Valkenburg
A1 Gaya K Amarasinghe
A1 Eric HY Lau
A1 David S Hui
A1 Gabriel M Leung
A1 Malik Peiris
A1 Joseph T Wu
YR 2022
UL http://medrxiv.org/content/early/2022/11/03/2022.11.01.22281746.abstract
AB The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and escape of vaccine-derived immunity. While current vaccines remain effective against severe disease and death, robust evidence on vaccine effectiveness (VE) against all Omicron infections (i.e. irrespective of symptoms) remains sparse. We addressed this knowledge-gap using a community-wide serosurvey with 5,310 subjects by estimating how vaccination histories modulated risk of infection in Hong Kong (which was largely infection naïve) during a large wave of Omicron epidemic during January-July 2022. We estimated that Omicron infected 45% (41-48%) of the Hong Kong population. Three and four doses of BNT162b2 or CoronaVac were effective against Omicron infection (VE of 47% (95% credible interval 34-68%) and 70% (43-99%) for three and four doses of BNT162b2 respectively; VE of 31% (1-73%) and 59% (10-99%) for three and four doses of CoronaVac respectively) seven days after vaccination, but protection waned with half-lives of 15 (3-47) weeks for BNT162b2 and 5 (1-37) weeks for CoronaVac. Our findings suggest that booster vaccination can temporarily enhance population immunity ahead of anticipated waves of infections.Competing Interest StatementA Hachim, N Kavian, LLM Poon, JSM Peiris and SA Valkenburg have filed an IDF (US 63/016,898) for the use of ORF8 and ORF3b as diagnostics of SARS-CoV-2 infection. M Mori produced ORF8 by patent process based on US Patents 8,507,220 and 8,586,826. Other authors have no declaration of interest.Funding StatementWe thank the following agencies from The Government of Hong Kong Special Administrative Region for compiling the data used in this research: Office of the Government Chief Information Officer (OGCIO), Department of Health, Centre for Health Protection and the Environmental Protection Department (see Data Availability for details). The study was supported by the Health and Medical Research Fund - Commissioned Research on the Novel Coronavirus Disease (COVID-19) (reference nos. COVID190126) from the Health Bureau, by AIR@InnoHK administered by Innovation and Technology Commission, both of the Government of the Hong Kong Special Administrative Region, and the Theme based Research Grants Scheme (T11- 712/19-N, SAV) of the Hong Kong Special Administrative Region. JJ Lau is supported by the University of Hong Kong Presidential PhD Scholarship. The authors thank Dr. Jennifer Leung, Sr. Chelly Chu and Sr. Cathy Chan from the Hong Kong Red Cross Blood Transfusion Service, and Dr. Tommy Lam, Dominic Chan, Hermione Kock, Stephy Lam, Melanie Ngai, Zoe Song, Miky Wong and Nicole Wong from the School of Public Health, The University of Hong Kong, for research support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the Institutional Review Board of the Hospital Authority Hong Kong West Cluster / University of Hong Kong (IRB No. UW 20-132).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymized vaccination record data were compiled by the Office of the Government Chief Information Officer (OGCIO) and the Department of Health, The Government of Hong Kong Special Administrative Region (HKSAR). Age data for confirmed cases were compiled by the Centre for Health Protection. Data on viral load from sewage surveillance were compiled by the Environmental Protection Department, The Government of HKSAR. The aforementioned data could not be shared due to confidentiality undertakings to the above-named agencies. Interested parties could contact these agencies for access to these data. Anonymized serology output data are available from the authors upon request. Outputs of our analysis and other source data are accessible at https://github.com/jonathanjlau- hku/hkserosurvey2022.